S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
Log in

NYSEAMERICAN:NAVB - Navidea Biopharmaceuticals Stock Price, Forecast & News

$1.12
+0.08 (+7.69 %)
(As of 02/20/2020 04:00 PM ET)
Today's Range
$1.05
Now: $1.12
$1.14
50-Day Range N/A
52-Week Range
$0.49
Now: $1.12
$4.20
Volume266,249 shs
Average Volume162,786 shs
Market Capitalization$20.25 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSEAMERICAN:NAVB
Previous SymbolNYSEMKT:NAVB
CUSIP63937X10
Phone+1-614-7937500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees14
Market Cap$20.25 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive NAVB News and Ratings via Email

Sign-up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.


Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) announced its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.17). The biopharmaceutical company earned $0.24 million during the quarter. View Navidea Biopharmaceuticals' Earnings History.

When is Navidea Biopharmaceuticals' next earnings date?

Navidea Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Navidea Biopharmaceuticals.

What price target have analysts set for NAVB?

2 brokerages have issued 1 year price objectives for Navidea Biopharmaceuticals' stock. Their forecasts range from $2.00 to $3.00. On average, they anticipate Navidea Biopharmaceuticals' share price to reach $2.50 in the next year. This suggests a possible upside of 123.2% from the stock's current price. View Analyst Price Targets for Navidea Biopharmaceuticals.

What is the consensus analysts' recommendation for Navidea Biopharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Navidea Biopharmaceuticals.

Has Navidea Biopharmaceuticals been receiving favorable news coverage?

Media headlines about NAVB stock have been trending somewhat negative on Thursday, InfoTrie reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Navidea Biopharmaceuticals earned a daily sentiment score of -1.9 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Navidea Biopharmaceuticals.

Are investors shorting Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals saw a decrease in short interest in January. As of January 31st, there was short interest totalling 664,900 shares, a decrease of 7.0% from the January 15th total of 715,300 shares. Based on an average daily volume of 608,700 shares, the short-interest ratio is currently 1.1 days. Approximately 6.0% of the shares of the stock are sold short. View Navidea Biopharmaceuticals' Current Options Chain.

Who are some of Navidea Biopharmaceuticals' key competitors?

What other stocks do shareholders of Navidea Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include NovaBay Pharmaceuticals (NBY), Opko Health (OPK), Rexahn Pharmaceuticals (REXN), Agenus (AGEN), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), Novavax (NVAX), AcelRx Pharmaceuticals (ACRX) and Gilead Sciences (GILD).

Who are Navidea Biopharmaceuticals' key executives?

Navidea Biopharmaceuticals' management team includes the folowing people:
  • Mr. Jed A. Latkin, CEO, COO, CFO, Sec., Treasurer & Director (Age 45)
  • Dr. Michael Stanley Rosol Ph.D., Chief Medical Officer
  • Erika Gibson, Director of Fin. & Admin.
  • Mr. William J. Regan, Chief Compliance Officer (Age 67)
  • Ms. Sharon Correia, Sr. Director of Corp. Communications

Who are Navidea Biopharmaceuticals' major shareholders?

Navidea Biopharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Allred Capital Management LLC (0.13%). Company insiders that own Navidea Biopharmaceuticals stock include Claudine Bruck, Jed Latkin, John K Jr Scott and Sarah Kathryn Rouan. View Institutional Ownership Trends for Navidea Biopharmaceuticals.

Which institutional investors are buying Navidea Biopharmaceuticals stock?

NAVB stock was bought by a variety of institutional investors in the last quarter, including Allred Capital Management LLC. Company insiders that have bought Navidea Biopharmaceuticals stock in the last two years include Claudine Bruck, Jed Latkin, John K Jr Scott and Sarah Kathryn Rouan. View Insider Buying and Selling for Navidea Biopharmaceuticals.

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $1.12.

How big of a company is Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals has a market capitalization of $20.25 million. Navidea Biopharmaceuticals employs 14 workers across the globe.View Additional Information About Navidea Biopharmaceuticals.

What is Navidea Biopharmaceuticals' official website?

The official website for Navidea Biopharmaceuticals is http://www.navidea.com/.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.


MarketBeat Community Rating for Navidea Biopharmaceuticals (NYSEAMERICAN NAVB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  328
MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe NAVB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NAVB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel